Want to see OCGN full AI Analyst Report?
Top Page
Ocugen
(NASDAQ:OCGN)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.00
▼(-17.36% Downside)
Action:Reiterated
Date:08/07/26
OCGN’s score is primarily held back by weak financial performance—negative equity, rising debt, and sustained cash burn—despite improving revenue growth. The earnings call was a key offset, showing strong clinical/regulatory progress and extended cash runway, but with ongoing dilution/financing dependence. Technical signals remain bearish (below major moving averages with negative MACD), and valuation support is limited given the negative P/E and no dividend yield.
Positive Factors
Regulatory Progress (OCU410 RMAT)
FDA clearance to start a registrational Phase III and RMAT status materially de-risks OCU410’s development path. Over 2–6 months this supports accelerated regulatory engagement, increases the probability of timely BLA filing/priority review, and strengthens the program’s attractiveness to partners and payers.
Negative Factors
Negative Equity Position
A negative equity position is a persistent structural weakness that constrains financial flexibility and creditor confidence. Over the coming months it increases refinancing complexity, limits access to non-dilutive capital, and raises the probability that future financing terms will be more costly or dilutive.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress (OCU410 RMAT)
FDA clearance to start a registrational Phase III and RMAT status materially de-risks OCU410’s development path. Over 2–6 months this supports accelerated regulatory engagement, increases the probability of timely BLA filing/priority review, and strengthens the program’s attractiveness to partners and payers.
Read all positive factors
Ocugen (OCGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$466.28M
Dividend YieldN/A
Average Volume (3M)8.17M
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue Growth-3.66%
EPS Growth-28.98%
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding339,110,400
10 Day Avg. Volume4,592,933
30 Day Avg. Volume8,170,514
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.25Price Target Upside747.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$4.50M
Ocugen Business Overview & Revenue Model
Company Description
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features sev...
How the Company Makes Money
Ocugen is a clinical-stage company and, as such, its ability to generate recurring product revenue is limited; its business model primarily depends on external capital and, when available, collaboration-related income. In general, the company can ...
Ocugen Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.Positive Updates
Regulatory Milestones for OCU410 (GA)
FDA cleared the Phase 3 ArMaDa3 registrational trial for OCU410 to initiate dosing and granted RMAT designation. The Phase III is planned as a global ~237-subject adaptive trial powered at 95% with initiation targeted by September 2026 and BLA/MAA filings targeted for 2028.
Negative Updates
Rising Operating Expenses
Total operating expenses for Q2 2026 were $17.9M versus $15.2M in Q2 2025 (+17.8% year-over-year). R&D expense rose to $10.7M from $8.4M (+27.4%) and G&A rose to $7.2M from $6.8M (+5.9%). For the first 6 months, total operating expenses increased to $37.3M from $31.2M (+19.6%).
Read all updates
Q2-2026 Updates
Positive
Negative
Regulatory Milestones for OCU410 (GA)
FDA cleared the Phase 3 ArMaDa3 registrational trial for OCU410 to initiate dosing and granted RMAT designation. The Phase III is planned as a global ~237-subject adaptive trial powered at 95% with initiation targeted by September 2026 and BLA/MAA filings targeted for 2028.
Read all positive updates
Company Guidance
Ocugen reiterated milestone and financial guidance driven by successful execution: after a $130 million convertible note financing the company held $100.4 million in cash, cash equivalents and restricted cash as of June 30, 2026 (339 million shares outstanding) and expects cash runway into 2028 to support all three late‑stage programs and the target of filing 3 BLAs by 2028. Key operational timelines include initiating the OCU410 (GA) Phase III ArMaDa3 (~237 subjects, 2:1 randomization, 95% powered) by September 2026, an interim outcome decision for OCU410ST (GARDian3; 63 enrolled) on the first 50% of subjects at 8 months in Q3 2026 with top‑line OCU410ST data in Q2 2027 and a BLA mid‑2027, and top‑line OCU400 (liMeliGhT; 140 patients randomized 2:1) data in Q1 2027 with potential approval by Q4 2027; PPQ batches are complete to support BLA/commercial supply. Financials and safety metrics highlighted: Q2 2026 operating expenses $17.9M (R&D $10.7M; G&A $7.2M) vs. $15.2M a year ago, six‑month operating expenses $37.3M (R&D $21.9M; G&A $15.4M) vs. $31.2M, net loss per share $0.07 in Q2 2026 vs. $0.05, and across the platform >325 patients treated with no drug‑related serious adverse events; notable clinical signals include a 31% reduction in GA lesion growth and 27% ellipsoid zone preservation at the optimal OCU410 dose (lesion size 2.5–17.5 mm2). Additional financing levers discussed include a potential OCU410ST PRV ($100–$200M range), 10 million Janus Henderson warrants (exercise could bring ~$15M at $1.50 strike, expiring Aug 2027), ongoing BD/ licensing opportunities, and a planned shareholder meeting in September to increase authorized shares.Ocugen Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.58M | 4.41M | 4.05M | 6.04M | 2.49M | 0.00 |
| Gross Profit | 4.58M | 2.02M | 2.09M | 5.33M | 2.49M | 0.00 |
| EBITDA | -70.13M | -60.27M | -52.09M | -62.37M | -86.32M | -58.11M |
| Net Income | -81.81M | -67.85M | -54.05M | -63.08M | -86.80M | -58.37M |
Balance Sheet | ||||||
| Total Assets | 124.21M | 43.52M | 82.44M | 64.55M | 108.63M | 105.76M |
| Cash, Cash Equivalents and Short-Term Investments | 100.05M | 18.57M | 58.51M | 39.46M | 90.93M | 94.96M |
| Total Debt | 87.99M | 33.14M | 32.50M | 6.94M | 6.37M | 3.31M |
| Total Liabilities | 140.76M | 55.68M | 52.81M | 23.98M | 34.65M | 9.94M |
| Stockholders Equity | -16.56M | -12.17M | 29.63M | 40.56M | 73.98M | 95.82M |
Cash Flow | ||||||
| Free Cash Flow | -61.38M | -57.15M | -45.53M | -72.53M | -64.54M | -48.88M |
| Operating Cash Flow | -61.23M | -56.96M | -42.14M | -62.05M | -60.08M | -47.94M |
| Investing Cash Flow | -148.00K | -311.00K | -3.38M | 3.08M | -16.97M | -1.82M |
| Financing Cash Flow | 120.36M | 17.33M | 64.86M | 20.88M | 59.48M | 120.68M |
Ocugen Technical Analysis
Neutral
1.21
Price Trends
1.34
Positive
1.47
Negative
1.51
Negative
Market Momentum
<0.01
Negative
50.94
Neutral
63.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCGN, the sentiment is Neutral. The current price of 1.21 is below the 20-day moving average (MA) of 1.29, below the 50-day MA of 1.34, and below the 200-day MA of 1.51, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.94 is Neutral, neither overbought nor oversold. The STOCH value of 63.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OCGN.
Ocugen Risk Analysis
Ocugen disclosed 7 risk factors in its most recent earnings report. Ocugen reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ocugen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.59B | -11.55 | -63.58% | ― | -62.28% | 15.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $466.28M | -5.29 | 1688.22% | ― | -3.66% | -28.98% | |
50 Neutral | $460.27M | -7.80 | -0.91% | ― | 8.78% | -227.47% | |
46 Neutral | $140.43M | -1.66 | 44.63% | ― | 3.03% | 57.71% | |
43 Neutral | $1.31B | -7.06 | -43.31% | ― | -83.86% | -646.52% |
* Healthcare Sector Average
OCGN
Ocugen
1.34
0.34
34.00%
SVA
Sinovac Biotech
6.47
0.00
0.00%
ADCT
ADC Therapeutics
1.03
-2.08
-66.88%
GLUE
Monte Rosa Therapeutics
15.03
10.63
241.59%
ABSI
AbSci
8.85
6.23
237.79%
Ocugen Corporate Events
Business Operations and Strategy
Ocugen inks OCU400 licensing deal for MENA
Positive
Jul 13, 2026
On July 13, 2026, Ocugen announced it had signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to grant exclusive rights to OCU400, its modifier gene therapy for retinitis pigmentosa, in the...
Executive/Board ChangesShareholder Meetings
Ocugen Stockholders Approve Proposals and Confirm Leadership
Positive
Jun 11, 2026
On June 11, 2026, Ocugen held its 2026 Annual Meeting of Stockholders virtually, where shareholders elected Kirsten Castillo and Satish Chandran as Class III directors to serve until the 2029 annual meeting and ratified PricewaterhouseCoopers LLP ...
Executive/Board Changes
Ocugen Consolidates Financial Leadership Under New Accounting Officer
Neutral
Jun 3, 2026
Ocugen, Inc. reported that Chief Accounting Officer Ramesh Ramachandran resigned effective May 29, 2026, where he had served as the company’s principal accounting officer. The move marks a notable change in the finance leadership structure a...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Raises $130 Million Through Convertible Notes Offering
Positive
May 14, 2026
On May 7, 2026, Ocugen closed a private offering of $115 million in 6.75% Convertible Senior Notes due 2034 and, on May 14, 2026, issued an additional $15 million after the full exercise of the over-allotment option, bringing the total to $130 mil...
Business Operations and StrategyExecutive/Board Changes
Ocugen Announces Interim Chief Medical Officer Appointment Transition
Neutral
May 14, 2026
On May 8, 2026, Ocugen, Inc. saw the departure of its Chief Medical Officer, Huma Qamar, M.D., MPH, CMI, marking a notable change in the company’s senior medical leadership structure. On the same date, Ocugen appointed Mohamed Genead, M.D., ...
Business Operations and StrategyPrivate Placements and Financing
Ocugen Raises Capital Through Convertible Senior Notes Offering
Positive
May 7, 2026
On May 7, 2026, Ocugen, Inc. completed a private offering of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, issued as unsecured senior obligations with detailed conversion, redemption and default provisions. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.